

Press Release

NOTIFICATION OF INTEREST IN SHARES

TR-1: Notifications of Major Interests in Shares							
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:				ProStrakan Group plc			
2. Reason for notification (yes/no)							
An acquisition or disposal of voting rights						YES	
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached							
An event changing the breakdown of voting rights							
Other (please specify):							
3. Full name of person(s) subject to notification obligation:				3i Group plc (direct) 3i Investments plc (indirect)			
4. Full name of shareholder(s) (if different from 3):				N/A			
5. Date of transaction (and date on which the threshold is crossed or reached if different):				28/11/2008			
6. Date on which issuer notified:				2/12/2008			
7. Threshold(s) that is/are crossed or reached:				6%			
8: Notified Details							
A: Voting rights attached to shares							
Class/type of shares <small>If possible use ISIN code</small>	Situation previous to the triggering transaction		Resulting situation after the triggering transaction				
	Number of shares	Number of voting rights	Number of shares	Number of voting rights		Percentage of voting rights	
				Direct	Indirect	Direct	Indirect
GB00B09 STF21	12,156,515	12,156,515	11,901,620	11,901,620	See section 9 below	5.9142	See section 9 below

B: Financial Instruments				
Resulting situation after the triggering transaction				
Type of financial instrument	Expiration date	Exercise/ conversion period/date	No. of voting rights that may be acquired (if the instrument exercised/converted)	Percentage of voting rights

Total (A+B)	
Number of voting rights	Percentage of voting rights
11,901,620	5.9142%

9. Chain of controlled undertakings through which the voting rights and /or the financial instruments are effectively held, if applicable:
<p>3i Group plc has a direct beneficial interest in the total number of voting rights disclosed in section 8 above.</p> <p>3i Investments plc (a wholly owned subsidiary of 3i Group plc) has an indirect interest in the total number of voting rights disclosed in section 8 above in its capacity as the discretionary Investment Manager of 3i Group plc</p> <p>3i Holdings plc and 3i plc are both wholly owned subsidiary undertakings of 3i Group plc and parent undertakings of 3i Investments plc</p>

Proxy Voting:	
10. Name of proxy holder:	
11. Number of voting rights proxy holder will cease to hold:	
12. Date on which proxy holder will cease to hold voting rights:	

13. Additional information:	Notification using total voting rights of 201,238,681
14 Contact name:	Jackie Harper
15. Contact telephone name:	020 7975 3530

For more information on this announcement, please contact:

ProStrakan +44 (0)1896 664000
Dr Wilson Totten, Chief Executive
Paul Garvey, Chief Financial Officer
Callum Spreng, Corporate Comms Director

Financial Dynamics +44 (0)20 7831 3113
David Yates / Ben Brewerton

Trout Group (for US investor enquiries)
Gitanjali Jain (646) 378-2949

ProStrakan

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office and development facilities are situated in Galashiels in Scotland. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain and other EU countries.
www.prostrakan.com